September 30, 2025

What periop nurses should preoperatively know about GLP-1, oral GLP-1 drugs

With the explosion of GLP-1–based therapies for type 2 diabetes and weight loss, perioperative nursing teams, especially in the preoperative and postanesthesia care areas, need to be fluent in recognizing these medications. Some patients may arrive on these agents—or even novel oral GLP-1s—and the physiologic effects, especially delayed gastric emptying, can influence anesthesia risk, aspiration precautions, and timing decisions.

This article aims to help perioperative nurse managers and advanced practice leaders recognize GLP-1 agents by name, understand relevant considerations, and partner with anesthesia and endocrinology to mitigate risk.

 

Recognizing major GLP-1, related agents

GLP-1 (glucagon-like peptide-1) receptor agonists (GLP-1 RAs) are a class of medications that mimic the incretin hormone GLP-1. They enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety/weight loss. Many GLP-1 RAs are peptides or analogs and are delivered via subcutaneous injection; some newer ones are taken orally. In addition, dual or multi-agonist agents (eg, GLP-1 + GIP) are in use or development (eg, tirzepatide) and may share many of the same concerns.

A recently described oral small-molecule GLP-1 agonist, orforglipron, is being developed for weight loss/diabetes. Orforglipron is a once-daily pill under clinical investigation. Because it is investigational—meaning it is still in clinical trials and not approved by the US Food and Drug Administration—it would only appear on a medication list if the patient is part of a research study. In such a situation, perioperative nurses should alert the anesthesia and surgical teams immediately, since clinical trial medications often have specific protocols about whether they can be held, continued, or need special documentation in the perioperative setting.

Below is a non-exhaustive list of GLP-1 / GLP-1–based agents commonly seen in clinical practice or emerging, with their dosing cadence and key notes. (This is useful for OR/preop nurses to flag in medication histories.)

Generic (trade name[s]) Dosing interval / route Notes / considerations
Exenatide (Byetta, Bydureon) Twice daily (Byetta), once weekly (Bydureon) One of the older GLP-1 agents
Lixisenatide (Adlyxin) Daily Short-acting GLP-1
Liraglutide (Victoza for diabetes, Saxenda for obesity) Daily Moderate half-life; GI side effects common; often used in weight loss contexts
Dulaglutide (Trulicity) Weekly Long-acting; slow washout
Semaglutide (Ozempic [weekly injectable], Rybelsus [oral daily], Wegovy [for weight]) Weekly (injectable) or daily (oral) Among the most used agents currently; oral semaglutide (Rybelsus) deserves special attention
Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) Weekly Dual GLP-1/GIP action; similar gastric effects expected
Orforglipron (in development) Oral daily (investigational) A non-peptide oral GLP-1 agonist in clinical development

Because these medications are relatively new in widespread use (especially for weight loss), many patients or even providers may not realize their significance in the surgical/anesthetic context. An OR nurse who sees “Rybelsus,” “Ozempic,” “Wegovy,” or “Trulicity” in the preop medication list should immediately consider whether the anesthetic team should adjust fasting or induction plans.

 

Why OR teams should recognize these drugs

1. Delayed gastric emptying, aspiration risk

One of the fundamental physiologic effects of GLP-1 RAs is slowing gastric motility (gastric emptying). Even when patients have fasted appropriately per standard preoperative guidelines, multiple reports and small studies have documented residual gastric contents in patients using GLP-1 therapy.

Because pulmonary aspiration is one of the most feared complications under anesthesia, delayed gastric emptying is a nontrivial risk that anesthesiologists (and affiliated nursing teams) want to mitigate.

2. Fasting and “full stomach” planning

If a patient on a GLP-1 agent is not managed appropriately, the anesthesiologist may need to treat them as having a “full stomach” (eg, rapid sequence induction, modified techniques). Some guidance suggests using preoperative gastric ultrasound to stratify risk. Nurses in preop can flag these patients early so anesthesia and surgical teams can plan accordingly.

3. Balancing glycemic control vs discontinuation risk

Stopping a GLP-1 agent before surgery may worsen glycemic control, increase insulin requirements, or precipitate perioperative hyperglycemia. Avoiding abrupt discontinuation without plan (or “bridging”) may also create patient discomfort or rebound GI side effects. The decision whether to pause or continue a GLP-1 agent perioperatively must be individualized, often in consultation with endocrinology/medicine, and communicated early.

4. Emerging data on outcomes, delay windows, risk stratification

Recent literature is evolving rapidly. For example:

  • Some consensus statements recommend pausing daily GLP-1 agents on the day of surgery, and pausing weekly agents a week ahead in elective cases.
  • Other newer guidelines suggest continuing GLP-1 therapy perioperatively in many patients, especially those without significant GI symptoms, to avoid undermining glycemic control.
  • A recent study (in an orthopedic surgery context) suggested that stopping semaglutide at least 14 days before total joint arthroplasty reduced complications (eg aspiration, delayed emergence) compared to shorter discontinuation intervals.
  • Anesthesia societies and perioperative groups caution the evidence is still limited; improved protocols (including use of gastric ultrasound, individualized fasting periods, prokinetic agents) are under discussion.

Because recommendations are shifting, perioperative nursing leadership should stay abreast of institutional protocols, evolving ASA or anesthesiology guidance, and endocrinology best practices.

 

Preop operational recommendations

1. Update preoperative questionnaires/medication checklists

  • Include a prompt: “GLP-1 / weight loss injectables or oral (eg, Ozempic, Rybelsus, Wegovy, Trulicity, Mounjaro, etc)?”
  • Educate front-desk, intake, and preop staff to flag these.

2. Develop a “GLP-1 flag protocol”

  • Once flagged, preop nursing should alert anesthesiology and the surgical team for further discussion (sidebar, Sample preop alert language).
  • Consider issuing a “GLP-1 alert” sticker or symbol on the chart to highlight potential gastric emptying issues.

3. Coordinate with anesthesia and endocrine/medicine teams

  • Establish a consensus or institutional protocol about whether to continue, pause, or modify GLP-1 therapy before surgery, depending on patient risk and the specific drug.
  • Use risk stratification (urgent vs elective surgery, GI symptoms, comorbid gastroparesis, etc).

4. Fasting and intake modifications

  • For higher-risk patients, consider more conservative fasting strategies (eg, extended fasting, clear fluid restrictions, residue-free diets) in consultation with anesthesia.
  • Preoperative administration of prokinetic agents (eg, erythromycin, metoclopramide) is sometimes proposed, although it may theoretically counteract GLP-1 gastric effects.

5. Gastric ultrasound or point-of-care tools

  • In facilities where gastric ultrasound assessment is available, use it to estimate residual gastric contents in flagged patients.
  • This data can guide decision-making (delay, treat as full stomach, or proceed).

6. Educate your team and reinforce awareness

  • Conduct inservice or grand rounds to make OR/preop staff aware of GLP-1 names, risks, and current institutional policies.
  • Update orientation materials for new nursing staff to include GLP-1 safety alerts.

7. Monitor outcomes and feedback loops

  • Track any intraoperative events (aspirations, delays in induction, unplanned conversions) associated with GLP-1 patients.
  • Review protocols periodically in light of emerging literature.

 

Caveats, limitations, future directions

Despite the growing attention to GLP-1 receptor agonists in the perioperative setting, the available evidence remains limited. Much of what is known today comes from case reports, small observational series, and expert consensus rather than large randomized controlled trials. This means that many recommendations—including how long to withhold these medications prior to surgery—are based on clinical judgment and evolving best practices rather than definitive data.

A key challenge is balancing the benefits of continuing GLP-1 therapy, such as improved glycemic control and cardiometabolic outcomes, against the potential aspiration risk associated with delayed gastric emptying. Different guidelines vary in their recommendations, with some suggesting discontinuation a week or more in advance of elective procedures and others supporting continuation in many patients, especially those without significant gastrointestinal symptoms.

Adding to the complexity, new GLP-1 agents—particularly oral small-molecule drugs such as orforglipron—are advancing through clinical trials. These agents may have unique pharmacokinetics that further alter perioperative management strategies. As these drugs reach clinical practice, institutional protocols will need to adapt accordingly.

Ultimately, there is broad agreement that more robust evidence is needed. Large prospective studies and randomized trials will be essential to better quantify the actual risk of aspiration, to determine optimal discontinuation intervals, and to identify safe and effective perioperative management strategies. Until then, perioperative teams should remain vigilant, apply institutional protocols, and maintain close interdisciplinary communication when caring for patients on GLP-1 therapy.

As GLP-1 receptor agonist use (injectable and oral) continues to grow, perioperative teams cannot afford to ignore them. By making GLP-1 awareness part of standard preoperative workflow, perioperative leaders help protect patients from aspiration risk and support smoother anesthetic planning.

 

—Tarsilla Moura is content director of OR Manager.

 

References

Alfaris N, Waldrop S, Johnson V, et al. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782. 

Beam W B, Guevara L R H. Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia. Anesthesia Patient Safety Foundation. 2023;38(3):Newsletter.

Dutta D, Nagendra L, Anne B, et al. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obes Sci Pract. 2024;10(2):e743.

El-Boghdadly K, Dhesi J, Fabb P, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: A multidisciplinary consensus statement. Anaesthesia: Association of Anaesthetists. 2025;80(4):412–424.

Gariani K, Putzu A. Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist. Eur J Anaesthesiol. 2024;41(3):245–246.

Kindel T L, Wang A Y, Wadhwa A, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgery for Obesity and Related Diseases. 2024;20(12):1183–1186.

Li X Y, Jin Y, Feng X Y, et al. Perioperative management of patients on GLP-1 receptor agonists: Risks, recommendations, and future directions, a narrative review. J Clin Anesth. 2025;104:111871.

Liu Q K. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292.

Mishra S, Persons P A, Bersoux S. Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period? Cleveland Clinic Journal of Medicine. 2025;92(4):209–211.

Most Patients Can Continue Diabetes, Weight Loss GLP-1 Drugs Before Surgery, Those at Highest Risk for GI Problems Should Follow Liquid Diet Before Procedure. American Society of Anesthesiologists. October 29, 2024 (last updated February 18, 2025).

New Study Recommends Stopping GLP-1 Agonists 14 Days Before Total Joint Arthroplasty to Reduce Anesthesia Risks. American Academy of Orthopaedic Surgeons. March 10, 2025.

Oprea A D, Ostapenko L J, Sweitzer B, et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement. Br J Anaesth. 2025;135(1):48–78.

Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634–2641.

Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.

Join our community

Learn More
Video Spotlight
Live chat by BoldChat